Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
CANTON, Mass., May 02, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 12:50 p.m. ET at the Intercontinental Hotel Boston.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
